MENU
+Compare
HALO
Stock ticker: NASDAQ
AS OF
May 22 closing price
Price
$53.75
Change
-$0.18 (-0.33%)
Capitalization
6.62B

HALO Halozyme Therapeutics Forecast, Technical & Fundamental Analysis

Halozyme Therapeutics Inc is a biotechnology company focused on developing and commercializing novel oncology therapies... Show more

Industry: #Biotechnology
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for HALO with price predictions
May 22, 2025

HALO in +1.19% Uptrend, rising for three consecutive days on May 21, 2025

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where HALO advanced for three days, in of 310 cases, the price rose further within the following month. The odds of a continued upward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where HALO's RSI Oscillator exited the oversold zone, of 35 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

HALO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In of 291 cases where HALO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on May 13, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on HALO as a result. In of 85 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for HALO turned negative on May 13, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 41 similar instances when the indicator turned negative. In of the 41 cases the stock turned lower in the days that followed. This puts the odds of success at .

HALO moved below its 50-day moving average on May 13, 2025 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for HALO crossed bearishly below the 50-day moving average on May 14, 2025. This indicates that the trend has shifted lower and could be considered a sell signal. In of 13 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where HALO declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock slightly better than average.

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. HALO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (13.736) is normal, around the industry mean (16.302). P/E Ratio (14.295) is within average values for comparable stocks, (59.789). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.190). Dividend Yield (0.000) settles around the average of (0.024) among similar stocks. P/S Ratio (6.390) is also within normal values, averaging (277.726).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

View a ticker or compare two or three
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

HALO is expected to report earnings to rise 5.41% to $1.17 per share on August 12

Halozyme Therapeutics HALO Stock Earnings Reports
Q2'25
Est.
$1.17
Q1'25
Beat
by $0.13
Q4'24
Beat
by $0.11
Q3'24
Beat
by $0.31
Q2'24
Beat
by $0.15
The last earnings report on May 06 showed earnings per share of $1.11, beating the estimate of 98 cents. With 1.44M shares outstanding, the current market capitalization sits at 6.62B.
A.I. Advisor
published General Information

General Information

a developer of recombinant human enzymes for the infertility, ophthalmology and oncology markets

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
12390 El Camino Real
Phone
+1 858 794-8889
Employees
373
Web
https://www.halozyme.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
PWZ23.25N/A
N/A
Invesco California AMT-Free Muni Bd ETF
JHMM58.77N/A
N/A
JHancock Multifactor Mid Cap ETF
VSDA50.61N/A
N/A
VictoryShares Dividend Accelerator ETF
EAPR27.23-0.05
-0.17%
Innovator Em Mkts Pwr Bffr ETF - Apr
IVRA15.76-0.09
-0.55%
Invesco Real Assets ESG ETF

HALO and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, HALO has been loosely correlated with AXON. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if HALO jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HALO
1D Price
Change %
HALO100%
-0.33%
AXON - HALO
47%
Loosely correlated
N/A
XENE - HALO
45%
Loosely correlated
+0.10%
VIR - HALO
39%
Loosely correlated
N/A
IDYA - HALO
38%
Loosely correlated
N/A
ARGX - HALO
36%
Loosely correlated
N/A
More